Epsilogen
PrivateLast Round
Series B
Extension
Sep 9, 2024
Total Funding Raised
$74.64M
Company Overview
Epsilogen is a biotechnology company that develops immunoglobulin E (IgE) antibodies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epsilogen Comparables
Compare Epsilogen with similar companies based on industry and business-model similarity.
Epsilogen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 9, 2024 | ||||
| Series B | Mar 2, 2022 | ||||
| Grant | Oct 22, 2020 | ||||
| Grant | Jul 20, 2020 | ||||
| Series A Extension | Apr 20, 2020 | ||||
Grant | Apr 2, 2019 |
Key People
Founding team and executive leadership
Epsilogen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| UK government | Grant |
| Epidarex Capital | Series B, Series A, Series A Extension, Series B Extension |
| 3B FUTURE Health Fund | Series B Extension, Series B |
| ALSA Ventures | Series B Extension, Series A, Series A Extension, Series B |
| British Patient Capital | Series B Extension, Series B |
| ALSA Holdings | Series B Extension, Series A, Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 7, 2025
Cristina Oliva appointed as Chief Medical Officer.
- Apr 9, 2025
Dr. Sonia Gulati appointed to the Board of Directors.
Epsilogen Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Epsilogen's valuation, stock price, and market status.